What is GRAL's current stock price?

GRAL (GRAIL, Inc.) is currently trading at $67.19 with a market cap of $2.88B.

What sector is GRAIL, Inc. in?

GRAIL, Inc. (GRAL) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.

Is GRAL a good stock to buy?

Analysts have a Hold consensus on GRAL with a price target of $75.67. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

GRAL GRAIL, Inc.

Healthcare

$67.19-0.99%ClosedMarket Cap: $2.88B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.09

P/S

18.47

EV/EBITDA

-7.95

DCF Value

$-39.15

FCF Yield

-10.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

-14.8%

Operating Margin

-348.7%

Net Margin

-253.2%

ROE

-16.4%

ROA

-14.1%

ROIC

-15.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$40.8M	$-93.2M	$—
Q4 null	$43.6M	$-99.2M	$—
FY null	$147.2M	$-408.4M	$—
Q3 null	$36.2M	$-89.0M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$75.67

Target (Median)

$65.00

Target Range

$56.00 - $130.00

0 Strong Buy4 Buy4 Hold0 Sell0 Strong Sell

Piper SandlerNeutral

2026-05-06

TD CowenBuy

2026-05-06

GuggenheimBuy

2026-03-30

Morgan StanleyEqual Weight

2026-02-24

BairdOutperform

2026-02-20

Trading Activity

Insider Trades

View All

SUMME GREGORY Ldirector

SellFri Apr 17

MIZELL STEVENdirector

SellFri Apr 17

CHASE WILLIAM Jdirector

SellFri Apr 17

RAGUSA ROBERT Pdirector, officer: Chief Executive Officer

SellThu Apr 09

Ofman Joshua J.director, officer: President

SellThu Apr 09

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

Exchange

—

Beta

3.04

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Peers

DYN